People | January 21, 2022
DefiniGen promotes Dr Chris Kirton to CEO
The appointment is key for DefiniGEN as they expand the service portfolio to encompass compound screening
The appointment is key for DefiniGEN as they expand the service portfolio to encompass compound screening
Biocon has reported consolidated financial results for the period ended December 31, 2021
Phase 1/2 trial of E-602 expected to open in Q1 2022 in patients with solid tumours
Quviviq is a dual orexin receptor antagonist, which blocks the binding of the wake-promoting neuropeptides orexins and is thought to turn down overactive wakefulness, as opposed to treatments that generally sedate the brain
Nuvaxovid is the first protein-based Covid-19 vaccine to receive approval for provisional registration in Australia
The company will receive an upfront payment as well as regulatory and sales based milestone payments from Lotus
First launches expected in H1 2022
Bio-catalysis and Electro-catalysis emerge as most preferred green chemistry technologies
They will commercialize molnupiravir in the international markets
Narayanan to lead SeQuent through next phase of consolidation and growth
Subscribe To Our Newsletter & Stay Updated
